Open-label Multi-cohort Study of the Tolerability, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers After a Single Intravenous Injection in Increasing Doses
Latest Information Update: 16 Jul 2024
At a glance
- Drugs GNR 055 (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors GENERIUM Pharmaceuticals
Most Recent Events
- 02 Jul 2024 New trial record